518 related articles for article (PubMed ID: 18375007)
21. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.
Krause M; Schütze C; Petersen C; Pimentel N; Hessel F; Harstrick A; Baumann M
Radiother Oncol; 2005 Feb; 74(2):109-15. PubMed ID: 15734198
[TBL] [Abstract][Full Text] [Related]
22. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
Mason KA; Kishi K; Hunter N; Buchmiller L; Akimoto T; Komaki R; Milas L
Clin Cancer Res; 1999 Dec; 5(12):4191-8. PubMed ID: 10632360
[TBL] [Abstract][Full Text] [Related]
23. The response of a transplantable tumor to fractionated irradiation. 1. X rays and the hypoxic cell radiosensitizer Ro-07-0582.
Denekamp J; Harris SR
Radiat Res; 1976 Apr; 66(1):66-75. PubMed ID: 1257411
[No Abstract] [Full Text] [Related]
24. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.
Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L
Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567
[TBL] [Abstract][Full Text] [Related]
25. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies.
Yaromina A; Zips D; Thames HD; Eicheler W; Krause M; Rosner A; Haase M; Petersen C; Raleigh JA; Quennet V; Walenta S; Mueller-Klieser W; Baumann M
Radiother Oncol; 2006 Nov; 81(2):122-9. PubMed ID: 16956683
[TBL] [Abstract][Full Text] [Related]
26. Lack of differential radiosensitization of hypoxic cells in a mouse tumor at low radiation doses per fraction by cisplatin.
Sun JR; Brown JM
Radiat Res; 1993 Feb; 133(2):252-6. PubMed ID: 8438067
[TBL] [Abstract][Full Text] [Related]
27. The effect of misonidazole in combination with radiation dose fractionation.
Hill RP; Bush RS
Br J Cancer Suppl; 1978 Jun; 3():255-8. PubMed ID: 277242
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation.
Horsman MR
Int J Hyperthermia; 2015; 31(5):453-9. PubMed ID: 25915829
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
30. Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum.
Lukacova S; Khalil AA; Overgaard J; Alsner J; Horsman MR
Int J Radiat Biol; 2005 Dec; 81(12):937-44. PubMed ID: 16524849
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of nitrobenzimidazoles as hypoxic cell radiosensitizers.
Wright J; Frank LR; Bush D; Harrison GH
Radiat Res; 1983 Jul; 95(1):187-96. PubMed ID: 6348867
[TBL] [Abstract][Full Text] [Related]
32. Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo.
Krause M; Wohlfarth J; Georgi B; Pimentel N; Dorner D; Zips D; Eicheler W; Hessel F; Short SC; Joiner MC; Baumann M
Int J Radiat Biol; 2005 Oct; 81(10):751-8. PubMed ID: 16449082
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel.
Milas L; Hunter NR; Mason KA; Kurdoglu B; Peters LJ
Cancer Res; 1994 Jul; 54(13):3506-10. PubMed ID: 7912167
[TBL] [Abstract][Full Text] [Related]
34. Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors.
Ono K; Takahashi M; Nishidai T; Dodo Y; Shibamoto Y; Hiraoka M; Yukawa Y; Abe M
Radiat Med; 1984; 2(1):71-5. PubMed ID: 6242712
[TBL] [Abstract][Full Text] [Related]
35. The effect of hypoxic radiosensitizer after mild hyperthermia in C3H mammary carcinoma.
Ohizumi Y; Murayama C; Maezawa H; Mori T
Tokai J Exp Clin Med; 1984 Oct; 9(4):331-7. PubMed ID: 6537042
[TBL] [Abstract][Full Text] [Related]
36. Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?
Yaromina A; Hölscher T; Eicheler W; Rosner A; Krause M; Hessel F; Petersen C; Thames HD; Baumann M; Zips D
Radiother Oncol; 2005 Aug; 76(2):206-12. PubMed ID: 16024121
[TBL] [Abstract][Full Text] [Related]
37. Interactions of radiation, cyclophosphamide and nimorazole in a C3H mammary carcinoma in vivo.
Zachariae C; Overgaard J
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1445-8. PubMed ID: 3759571
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic gain factors for fractionated radiation treatment of spontaneous murine tumors using fast neutrons, photons plus O2(1) or 3 ATA, or photons plus misonidazole.
Suit HD; Sedlacek R; Silver G; Hsieh CC; Epp ER; Ngo FQ; Roberts WK; Verhey L
Radiat Res; 1988 Dec; 116(3):482-502. PubMed ID: 3205910
[TBL] [Abstract][Full Text] [Related]
39. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
Papadopoulou MV; Bloomer WD; Hollingshead MG
Anticancer Res; 2005; 25(3B):1865-9. PubMed ID: 16158918
[TBL] [Abstract][Full Text] [Related]
40. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
